(Q38003186)

26 August 2017

title

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (English)

1 reference

26 August 2017

Derick Wade

1

0 references

language of work or name

1 reference

1 April 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4 Suppl

1 reference

26 August 2017

page(s)

9-14

1 reference

Marijuana dependence and its treatment

26 August 2017

cites work

1 reference

Treatment of cannabis use disorders: a review of the literature

21 January 2018

1 reference

Development of a rational scale to assess the harm of drugs of potential misuse

21 January 2018

1 reference

Pharmacotherapy for cannabis dependence: how close are we?

21 January 2018

1 reference

Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence

21 January 2018

1 reference

21 January 2018

1 reference

Combined cannabinoid therapy via an oromucosal spray

21 January 2018

1 reference

Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults

21 January 2018

1 reference

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

21 January 2018

1 reference

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

21 January 2018

1 reference

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.12.12

1 reference

26 August 2017

1 reference